• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

帕博利珠单抗联合铂类双药治疗 PD-L1 低表达肺肉瘤样癌的显著疗效：一例报告。

Remarkable response to pembrolizumab with platinum-doublet in PD-L1-low pulmonary sarcomatoid carcinoma: A case report.

机构信息

Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Molecular Pharmacology Program and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

出版信息

Thorac Cancer. 2021 Apr;12(7):1126-1130. doi: 10.1111/1759-7714.13890. Epub 2021 Feb 19.

DOI:10.1111/1759-7714.13890
PMID:33605089
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8017259/
Abstract

Pulmonary sarcomatoid carcinoma (SC) is an aggressive subtype of lung cancer that exhibits resistance to cytotoxic chemotherapy. Although programmed cell death 1 (PD-1) inhibitors have been reported to show antitumor effects in patients with high programmed death-ligand 1 (PD-L1) expressing SC, the efficacy of combined therapy with PD-1 inhibitor plus cytotoxic chemotherapy has not previously been clarified. We herein report a case of SC with low expression of PD-L1 and few pre-existing tumor-infiltrating lymphocytes which showed a remarkable response to pembrolizumab plus cytotoxic chemotherapy as first-line treatment. Our findings suggest that combined treatment might enhance the immunogenic response, even in immunologically ignored SCs.

摘要

肺肉瘤样癌（SC）是一种侵袭性肺癌亚型，对细胞毒化疗具有耐药性。虽然程序性细胞死亡 1（PD-1）抑制剂已被报道在高表达程序性死亡配体 1（PD-L1）的 SC 患者中具有抗肿瘤作用，但 PD-1 抑制剂联合细胞毒化疗的疗效此前尚未阐明。我们在此报告一例 PD-L1 低表达且预先存在的肿瘤浸润淋巴细胞较少的 SC 病例，其对帕博利珠单抗联合细胞毒化疗作为一线治疗表现出显著的反应。我们的研究结果表明，联合治疗可能增强免疫原性反应，即使在免疫忽视的 SC 中也是如此。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58ad/8017259/c029fa197543/TCA-12-1126-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58ad/8017259/fe24cfcaea3b/TCA-12-1126-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58ad/8017259/f2ddf04d14ce/TCA-12-1126-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58ad/8017259/53c41010dbb6/TCA-12-1126-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58ad/8017259/c029fa197543/TCA-12-1126-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58ad/8017259/fe24cfcaea3b/TCA-12-1126-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58ad/8017259/f2ddf04d14ce/TCA-12-1126-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58ad/8017259/53c41010dbb6/TCA-12-1126-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/58ad/8017259/c029fa197543/TCA-12-1126-g005.jpg

相似文献

1
Remarkable response to pembrolizumab with platinum-doublet in PD-L1-low pulmonary sarcomatoid carcinoma: A case report. 帕博利珠单抗联合铂类双药治疗 PD-L1 低表达肺肉瘤样癌的显著疗效：一例报告。
Thorac Cancer. 2021 Apr;12(7):1126-1130. doi: 10.1111/1759-7714.13890. Epub 2021 Feb 19.
2
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.KEYNOTE-189 更新分析：帕博利珠单抗或安慰剂联合培美曲塞和铂类化疗用于未经治疗的转移性非鳞状非小细胞肺癌。
J Clin Oncol. 2020 May 10;38(14):1505-1517. doi: 10.1200/JCO.19.03136. Epub 2020 Mar 9.
3
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.帕博利珠单抗联合化疗对比单纯化疗用于无肿瘤 PD-L1 表达的晚期非小细胞肺癌患者：3 项随机对照研究的汇总分析。
Cancer. 2020 Nov 15;126(22):4867-4877. doi: 10.1002/cncr.33142. Epub 2020 Sep 11.
4
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.免疫治疗与非小细胞肺癌患者生存及免疫相关生物标志物的相关性：一项荟萃分析和个体患者水平分析。
JAMA Netw Open. 2019 Jul 3;2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879.
5
Neoadjuvant treatment of pembrolizumab plus platinum-doublet chemotherapy in stage IIIA squamous cell carcinoma of the lung: a case report.帕博利珠单抗联合铂类双药化疗用于ⅢA期肺鳞状细胞癌的新辅助治疗：一例病例报告
Ann Palliat Med. 2021 Mar;10(3):3510-3517. doi: 10.21037/apm-21-335.
6
Remarkable Alteration of PD-L1 Expression after Immune Checkpoint Therapy in Patients with Non-Small-Cell Lung Cancer: Two Autopsy Case Reports.免疫检查点治疗后非小细胞肺癌患者 PD-L1 表达的显著改变：两例尸检病例报告。
Int J Mol Sci. 2019 May 26;20(10):2578. doi: 10.3390/ijms20102578.
7
Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.晚期肺癌的联合化疗和程序性死亡受体 1/程序性死亡配体 1 抑制剂治疗的毒性管理。
Cancer Treat Rev. 2020 Apr;85:101979. doi: 10.1016/j.ctrv.2020.101979. Epub 2020 Feb 4.
8
Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?在联合化疗的情况下，哪种免疫疗法是晚期鳞状非小细胞肺癌的最佳选择：抗 PD-1 还是抗 PD-L1？
J Immunother Cancer. 2018 Dec 3;6(1):135. doi: 10.1186/s40425-018-0427-6.
9
Relationship Between Programmed Death Receptor-Ligand 1 Expression and Response to Checkpoint Inhibitor Immunotherapy in Pulmonary Sarcomatoid Carcinoma: A Pooled Analysis.程序性死亡受体配体 1 表达与肺肉瘤样癌对检查点抑制剂免疫治疗反应的关系：汇总分析。
Clin Lung Cancer. 2020 Sep;21(5):e456-e463. doi: 10.1016/j.cllc.2020.02.022. Epub 2020 Mar 9.
10
Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.铂类化疗联合 PD-1/PD-L1 抑制剂：临床前和临床研究及作用机制。
Expert Opin Drug Deliv. 2021 Feb;18(2):187-203. doi: 10.1080/17425247.2021.1825376. Epub 2020 Oct 5.

引用本文的文献

1
Integrative genomic and transcriptomic profiling of pulmonary sarcomatoid carcinoma identifies molecular subtypes associated with distinct immune features and clinical outcomes.肺肉瘤样癌的综合基因组和转录组分析确定了与不同免疫特征和临床结果相关的分子亚型。
Cancer Innov. 2024 Apr 15;3(3):e112. doi: 10.1002/cai2.112. eCollection 2024 Jun.
2
Sintilimab combined with anlotinib as first-line treatment for advanced sarcomatoid carcinoma of head and neck: a case report and literature review.信迪利单抗联合安罗替尼作为头颈部晚期肉瘤样癌一线治疗：一例病例报告及文献综述
Front Oncol. 2024 Apr 24;14:1362160. doi: 10.3389/fonc.2024.1362160. eCollection 2024.
3

本文引用的文献

1
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.KEYNOTE-189 更新分析：帕博利珠单抗或安慰剂联合培美曲塞和铂类化疗用于未经治疗的转移性非鳞状非小细胞肺癌。
J Clin Oncol. 2020 May 10;38(14):1505-1517. doi: 10.1200/JCO.19.03136. Epub 2020 Mar 9.
2
Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma.免疫检查点抑制剂在肺肉瘤样癌中的疗效。
J Thorac Oncol. 2020 May;15(5):860-866. doi: 10.1016/j.jtho.2020.01.014. Epub 2020 Jan 25.
3
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
An advanced pulmonary sarcomatoid carcinoma patient harboring a BRAF mutation responds to dabrafenib and trametinib: a case report and literature review.
一名携带BRAF突变的晚期肺肉瘤样癌患者对达拉非尼和曲美替尼有反应：病例报告及文献综述
Front Oncol. 2023 Jul 21;13:1220745. doi: 10.3389/fonc.2023.1220745. eCollection 2023.
4
Targeted therapy for rare lung cancers: Status, challenges, and prospects.罕见肺癌的靶向治疗：现状、挑战与展望。
Mol Ther. 2023 Jul 5;31(7):1960-1978. doi: 10.1016/j.ymthe.2023.05.007. Epub 2023 May 13.
5
Survival outcomes and prognostic factors of lung cancer patients with the exon 14 skipping mutation: A single-center real-world study.具有外显子14跳跃突变的肺癌患者的生存结果和预后因素：一项单中心真实世界研究。
Front Oncol. 2023 Mar 9;13:1113696. doi: 10.3389/fonc.2023.1113696. eCollection 2023.
6
The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma.一线免疫检查点抑制剂在肺肉瘤样癌中的疗效和安全性分析。
Front Immunol. 2022 Oct 31;13:956982. doi: 10.3389/fimmu.2022.956982. eCollection 2022.
7
Anlotinib combined with chemotherapy and immunotherapy for advanced pulmonary sarcomatoid cancer: a case report and literature review.安罗替尼联合化疗及免疫治疗晚期肺肉瘤样癌：一例报告及文献复习
Ann Transl Med. 2022 Sep;10(18):1030. doi: 10.21037/atm-22-4312.
8
Use of PD-1 inhibitor tislelizumab in the treatment of advanced pulmonary sarcomatoid carcinoma: A case report.使用 PD-1 抑制剂替雷利珠单抗治疗晚期肺肉瘤样癌：一例报告。
Thorac Cancer. 2022 Feb;13(3):502-505. doi: 10.1111/1759-7714.14290. Epub 2021 Dec 24.
阿替利珠单抗联合卡铂加白蛋白紫杉醇化疗与单纯化疗一线治疗转移性非鳞状非小细胞肺癌（IMpower130）：一项多中心、随机、开放标签、III 期临床试验。
Lancet Oncol. 2019 Jul;20(7):924-937. doi: 10.1016/S1470-2045(19)30167-6. Epub 2019 May 20.
4
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.帕博利珠单抗对比化疗用于未经治疗、PD-L1 表达、局部晚期或转移性非小细胞肺癌（KEYNOTE-042）：一项随机、开放标签、对照、III 期临床试验。
Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4.
5
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗治疗转移性非小细胞肺癌。
N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.
6
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.帕博利珠单抗对比化疗用于 PD-L1 阳性非小细胞肺癌。
N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Epub 2016 Oct 8.
7
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.纳武利尤单抗对比多西他赛治疗晚期非鳞状非小细胞肺癌
N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.
8
Classifying Cancers Based on T-cell Infiltration and PD-L1.基于T细胞浸润和PD-L1对癌症进行分类
Cancer Res. 2015 Jun 1;75(11):2139-45. doi: 10.1158/0008-5472.CAN-15-0255.
9
Objective measurement and clinical significance of TILs in non-small cell lung cancer.非小细胞肺癌中肿瘤浸润淋巴细胞的客观测量及其临床意义
J Natl Cancer Inst. 2015 Feb 3;107(3). doi: 10.1093/jnci/dju435. Print 2015 Mar.
10
PD-1 blockade induces responses by inhibiting adaptive immune resistance.程序性死亡受体1（PD-1）阻断通过抑制适应性免疫抵抗来诱导反应。
Nature. 2014 Nov 27;515(7528):568-71. doi: 10.1038/nature13954.